Castle Biosciences, Inc.

Contributing Author

Recent Articles by Castle Biosciences, Inc.

8 hours	Systematic Review and Meta-Analysis Confirms TissueCypher Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer CSTL GlobeNewswire
Dec-09	Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma CSTL GlobeNewswire
Nov-17	Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year CSTL GlobeNewswire
Nov-14	New Data Confirms Performance of DecisionDx-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity CSTL GlobeNewswire
Nov-11	Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference CSTL GlobeNewswire
Nov-03	Castle Biosciences Reports Third Quarter 2025 Results CSTL GlobeNewswire
Nov-03	Castle Biosciences Launches AdvanceAD-Tx to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis CSTL GlobeNewswire
Oct-28	Castle Biosciences to Participate in Upcoming Investor Conferences CSTL GlobeNewswire
Oct-26	New Data at American College of Gastroenterology Annual Meeting Show TissueCypher Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus CSTL GlobeNewswire
Oct-24	New Analysis of 13,560 Patients Demonstrates DecisionDx-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference CSTL GlobeNewswire
Oct-13	Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025 CSTL GlobeNewswire
Oct-01	Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine CSTL GlobeNewswire
Sep-23	Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award CSTL GlobeNewswire
Sep-17	Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025 CSTL GlobeNewswire
Sep-09	New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions CSTL GlobeNewswire
Aug-25	New Evidence Published Supporting Use of DecisionDx-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma CSTL GlobeNewswire
Aug-21	Castle Biosciences to Participate in Upcoming Investor Conferences CSTL GlobeNewswire
Aug-04	Castle Biosciences Reports Second Quarter 2025 Results CSTL GlobeNewswire
Jul-29	Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference CSTL GlobeNewswire
Jul-25	Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal CSTL GlobeNewswire
Jul-23	FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test CSTL GlobeNewswire
Jul-17	Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture CSTL GlobeNewswire
Jul-14	Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025 CSTL GlobeNewswire
Jun-19	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CSTL GlobeNewswire
Jun-16	Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases CSTL GlobeNewswire
Jun-11	Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention CSTL GlobeNewswire
Jun-04	Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards CSTL GlobeNewswire
May-29	New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes CSTL GlobeNewswire
May-21	Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference CSTL GlobeNewswire
May-09	Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result CSTL GlobeNewswire
May-07	Castle Biosciences Celebrates Skin Cancer Awareness Month CSTL GlobeNewswire
May-05	Castle Biosciences Reports First Quarter 2025 Results CSTL GlobeNewswire
May-05	Castle Biosciences to Acquire Previse CSTL GlobeNewswire
May-02	New Data at DDW 2025 Further Demonstrates the TissueCypher Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer CSTL GlobeNewswire

Castle Biosciences, Inc.

Recent Articles by Castle Biosciences, Inc.

Upgrade your FINVIZ experience